 |
市場調査レポート
商品コード
1290572
異常ヘモグロビン症市場：検査タイプ別、適応症別、エンドユーザー別、地域別-規模、シェア、展望、機会分析、2023～2030年Hemoglobinopathy Market, by Test Type, by Indication, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 異常ヘモグロビン症市場：検査タイプ別、適応症別、エンドユーザー別、地域別-規模、シェア、展望、機会分析、2023～2030年 |
|
出版日: 2023年05月10日
発行: Coherent Market Insights
ページ情報: 英文 170 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
異常ヘモグロビン症とは、ヘモグロビン分子の産生や構造に異常がある、遺伝性の疾患群です。異常ヘモグロビン症は、主に赤血球に影響を与える遺伝性の血液疾患および疾病のグループを指す医学用語です。鎌状赤血球症（SCD）は、異常なヘモグロビンが赤血球を傷つけ変形させることで起こる血液疾患の一つです。ヘモグロビン遺伝子の変異による構造型異常ヘモグロビン症と、正常なヘモグロビン分子が変化して起こるサラセミアに大別されます。主な構造型ヘモグロビン変異体は、HbS、HbE、HbCです。サラセミアの主な種類は、α-サラセミアとβ-サラセミアです。ヘモグロビン蛋白の異常を引き起こすいくつかの疾患は、ヘモグロビンの産生にも影響を与えるため、2つの疾患は重複することがあります。
ヘモグロビン異常の中には、病態や貧血を引き起こさないものもあり、そのため異常ヘモグロビン症として分類されないことも多いです。一般的な症状としては、激しい痛み、息切れ、脾臓の肥大、小児の成長障害などがあります。異常ヘモグロビン症は、赤血球中のヘモグロビンの異常によって引き起こされる疾患群です。
市場力学
製品ポートフォリオを拡大するために、市場の主要プレーヤーがパートナーシップなどの有機的成長戦略を採用することが増えており、予測期間中の市場成長を促進すると予想されます。例えば、2022年6月、米国の臨床段階の遺伝子編集企業として上場しているPrecision BioSciences社と製薬会社のNovartis AG社は、血液疾患に対する新しい遺伝子治療の開発に向けてパートナーシップを締結したと発表しています。
本調査の主な特徴
- 本レポートでは、世界の異常ヘモグロビン症市場を詳細に分析し、2022年を基準年とした予測期間（2023～2030年）の市場規模および年間平均成長率（CAGR%）を提供しています。
- さまざまなセグメントにおける潜在的な収益機会を解明し、この市場に対する魅力的な投資提案マトリクスを解説しています。
- また、市場促進要因、抑制要因、機会、新製品の発売または承認、市場動向、地域展望、主要企業が採用する競争戦略に関する重要な考察を提供します。
- 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略など、以下のパラメータに基づいて、世界の異常ヘモグロビン症市場における主要企業のプロファイルを掲載しています。
- この研究の一部としてカバーされている主要企業are Anamol Laboratories Pvt. Ltd., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Zentech, Sebia, Sysmex Europe SE, Nanjing Poclight Biotechnology Co., Ltd, Abbott, Danaher, ReachBio LLC, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Nexcelom Bioscience LLC., NIHON KOHDEN CORPORATION, Siemens Healthcare GmbH, CRISPR Therapeutics.。
- このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品の発売、タイプのアップグレード、市場の拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
- 世界の異常ヘモグロビン症市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
- 利害関係者は、世界のヘモグロビノパシー市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。
目次
第1章 調査目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場展望
- レポート概要
- 市場の定義と範囲
- エグゼクティブサマリー
- コヒーレント・オポチュニティ・マップ（COM）
第3章 市場力学、規制、動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 影響分析
- 主なハイライト
- 製品の発売
- 技術的進歩
- PEST分析
- 法規制のシナリオ
- M&A（合併・買収
第4章 異常ヘモグロビン症の世界市場-コロナウイルス（COVID-19）パンデミックの影響
- 経済的影響
- COVID-19の疫学について
- 需要と供給への影響
第5章 異常ヘモグロビン症の世界市場、検査タイプ別、2017年～2030年
- ルーチンの赤血球（RBC）カウント
- 遺伝子検査
- 高速液体クロマトグラフィー別ヘモグロビン検査
- ヘモグロビンの等電点集束（Hb IEF）
- ヘモグロビン電気泳動法（Hb ELP）
- ヘモグロビンの溶解度試験
第6章 異常ヘモグロビン症の世界市場、適応症別、2017年～2030年
- 鎌状赤血球症
- ベータサラセミア
- アルファサラセミア
第7章 異常ヘモグロビン症の世界市場、エンドユーザー別、2017年～2030年
- 病院
- 診断ラボ
- 診療所
第8章 異常ヘモグロビン症の世界市場：地域別、2017年～2030年
- 北米
- 米国
- カナダ
- ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他ラテンアメリカ
- 欧州
- 英国
- ドイツ
- イタリア
- フランス
- スペイン
- ロシア
- その他欧州
- アジア太平洋地域
- 中国
- インド
- 日本
- ASEAN
- オーストラリア
- 韓国
- その他アジア太平洋地域
- 中東地域
- GCC
- イスラエル
- その他中東地域
- アフリカ
- 北アフリカ
- 中央アフリカ
- 南アフリカ共和国
第9章 競合情勢
- Anamol Laboratories Pvt. Ltd.
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Zentech
- Sebia
- Sysmex Europe SE
- Nanjing Poclight Biotechnology Co., Ltd
- Abbott
- Danaher
- ReachBio LLC
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Nexcelom Bioscience LLC.
- NIHON KOHDEN CORPORATION
- Siemens Healthcare GmbH
- CRISPR Therapeutics
第10章 セクション
- 調査手法について
- 出版社について
目次
Product Code: CMI2801
Hemoglobinopathy are a group of disorders that are inherited, in which there is abnormal production or structure of the hemoglobin molecule. Hemoglobinopathy is the medical term for a group of inherited blood disorders and diseases that primarily affect red blood cells. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells. There are two main groups, which are abnormal structural hemoglobin variants caused by mutations in the hemoglobin genes, and the thalassemias, which are caused by an alteration in normal hemoglobin molecules. The main structural hemoglobin variants are HbS, HbE and HbC. The main types of thalassemia are alpha-thalassemia and beta thalassemia. The two conditions may overlap because some conditions, which cause abnormalities in hemoglobin proteins also affect their production.
Some hemoglobin variants do not cause pathology or anemia, and thus are often not classed as hemoglobinopathies. Common symptoms of the condition include, severe pain, shortness of breath, enlarged spleen, and growth problems in children. It can be any group of disorders caused by the presence of variant hemoglobin in the red blood cells.
Market Dynamics
Increasing adoption of organic growth strategies, such as partnerships by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2022, Precision BioSciences, a publicly traded American clinical stage gene editing company, and Novartis AG, a pharmaceutical corporation, announced that they have entered into a partnership to develop new gene therapy for blood disorders.
Key features of the study:
- This report provides in-depth analysis of the global hemoglobinopathy market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hemoglobinopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Anamol Laboratories Pvt. Ltd., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Zentech, Sebia, Sysmex Europe SE, Nanjing Poclight Biotechnology Co., Ltd, Abbott, Danaher, ReachBio LLC, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Nexcelom Bioscience LLC., NIHON KOHDEN CORPORATION, Siemens Healthcare GmbH, CRISPR Therapeutics.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy market
Detailed Segmentation:
- Global Hemoglobinopathy Market, By Test Type:
- Routine Red Blood Cell (RBC) count
- Genetic Testing
- Hemoglobin by high performance liquid chromatography
- Hemoglobin isoelectric focusing ( Hb IEF)
- Hemoglobin electrophoresis (Hb ELP)
- Hemoglobin solubility test
- Global Hemoglobinopathy Market, By Indication:
- Sickle Cell Disease
- Beta Thalassemia
- Alpha Thalassemia
- Global Hemoglobinopathy Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Clinics
- Global Hemoglobinopathy Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Anamol Laboratories Pvt. Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Zentech
- Sebia
- Sysmex Europe SE
- Nanjing Poclight Biotechnology Co., Ltd
- Abbott
- Danaher
- ReachBio LLC
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Nexcelom Bioscience LLC.
- NIHON KOHDEN CORPORATION
- Siemens Healthcare GmbH.
- CRISPR Therapeutics
- Anamol Laboratories Pvt. Ltd.*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Test Type
- Market Snapshot, By Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Hemoglobinopathy Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Hemoglobinopathy Market, By Test Type, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Routine Red Blood Cell (RBC) count
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Hemoglobin by high performance liquid chromatography
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Hemoglobin isoelectric focusing ( Hb IEF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Hemoglobin electrophoresis (Hb ELP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Hemoglobin solubility test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Hemoglobinopathy Market, By Indication, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Alpha Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Hemoglobinopathy Market, By End User, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segments Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global Hemoglobinopathy Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Anamol Laboratories Pvt. Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bio-Rad Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PerkinElmer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zentech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sebia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sysmex Europe SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Nanjing Poclight Biotechnology Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Danaher
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ReachBio LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Nexcelom Bioscience LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NIHON KOHDEN CORPORATION
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Siemens Healthcare GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CRISPR Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
